Top-Rated Stocks NASDAQ:RARE Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $45.43 -0.51 (-1.11%) (As of 02/7/2023 09:47 AM ET) Add Compare Share Share Today's Range$45.33▼$45.9450-Day Range$35.67▼$47.4452-Week Range$33.36▼$85.53Volume9,874 shsAverage Volume636,603 shsMarket Capitalization$3.19 billionP/E RatioN/ADividend YieldN/APrice Target$91.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ultragenyx Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside101.2% Upside$91.69 Price TargetShort InterestBearish5.50% of Float Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.81Based on 16 Articles This WeekInsider TradingSelling Shares$89,283 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.84) to ($7.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector352nd out of 1,027 stocksPharmaceutical Preparations Industry176th out of 500 stocks 3.4 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $91.69, Ultragenyx Pharmaceutical has a forecasted upside of 101.2% from its current price of $45.58.Amount of Analyst CoverageUltragenyx Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.50% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 3.2 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Ultragenyx Pharmaceutical this week, compared to 2 articles on an average week.Search Interest3 people have searched for RARE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,283.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions93.17% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($8.84) to ($7.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ultragenyx Pharmaceutical (NASDAQ:RARE) StockUltragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA.Read More Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on Ultragenyx Pharmaceutical Inc.'s FY2022 Earnings (NASDAQ:RARE)February 6, 2023 | americanbankingnews.comMorgan Stanley Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00February 7, 2023 | Investing Trends (Ad)Move Over Lithium – 220 Pounds of Graphite In Every EV BatteryInvestors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.February 5, 2023 | americanbankingnews.comUltragenyx Pharmaceutical Inc. to Post Q4 2023 Earnings of ($1.37) Per Share, Jefferies Financial Group Forecasts (NASDAQ:RARE)February 2, 2023 | americanbankingnews.comAnalyzing Ultragenyx Pharmaceutical (NASDAQ:RARE) & RespireRx Pharmaceuticals (OTCMKTS:RSPI)February 1, 2023 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by StockNews.comJanuary 13, 2023 | finance.yahoo.comBuy These 2 Stocks Before They Jump Over 80%, Say AnalystsJanuary 9, 2023 | finance.yahoo.comUltragenyx (RARE) Posts Preliminary '22 Results, Gives '23 ViewFebruary 7, 2023 | PressReach (Ad)One Stock To Watch CloselyToday's stock market news features a uranium stock with blue sky potential.January 7, 2023 | msn.comUltragenyx sees 2023 product revenue of $425M-$450MJanuary 6, 2023 | finance.yahoo.comUltragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 MilestonesJanuary 4, 2023 | finance.yahoo.comUltragenyx to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 30, 2022 | msn.comThe Latest Analyst Ratings for Ultragenyx PharmaceuticalDecember 16, 2022 | finance.yahoo.comUltragenyx's (RARE) Portfolio of Marketed Drugs Aids GrowthNovember 28, 2022 | bizjournals.comBig names, big dollars back Mahzi, a Peninsula drug startup targeting rare genetic brain disordersNovember 22, 2022 | finance.yahoo.comUltragenyx to Present at Piper Sandler Healthcare ConferenceNovember 21, 2022 | finance.yahoo.comUltragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 55% loss from investing in the stock a year agoNovember 18, 2022 | seekingalpha.comUltragenyx: Great Medicine, Good Execution, Stagnant StockNovember 10, 2022 | finance.yahoo.comUltragenyx Announces Departure of Chief Financial OfficerNovember 3, 2022 | nasdaq.comUltragenyx Pharma Q3 Loss WidensNovember 2, 2022 | finance.yahoo.comUltragenyx (RARE) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | finance.yahoo.comUltragenyx Reports Third Quarter 2022 Financial Results and Corporate UpdateOctober 27, 2022 | finance.yahoo.comUltragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate UpdateOctober 19, 2022 | seekingalpha.comAbeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder ValueSeptember 24, 2022 | uk.finance.yahoo.comUltragenyx Pharmaceutical Inc. (RARE)September 9, 2022 | finance.yahoo.comUltragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMRSeptember 6, 2022 | nasdaq.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) insiders sold US$2.9m worth of stock, possibly signalling a downtrendSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Company Calendar Last Earnings11/02/2021Today2/07/2023Next Earnings (Estimated)2/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$91.69 High Stock Price Forecast$142.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+101.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($9.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-454,020,000.00 Net Margins-197.47% Pretax Margin-195.38% Return on Equity-84.14% Return on Assets-41.25% Debt Debt-to-Equity RatioN/A Current Ratio4.45 Quick Ratio4.36 Sales & Book Value Annual Sales$351.41 million Price / Sales9.06 Cash FlowN/A Price / Cash FlowN/A Book Value$13.53 per share Price / Book3.36Miscellaneous Outstanding Shares70,110,000Free Float65,409,000Market Cap$3.19 billion OptionableOptionable Beta0.96 Key ExecutivesEmil D. KakkisPresident, Chief Executive Officer & DirectorDennis Karl HuangChief Technical Operations Officer & Senior VPSamuel C. WadsworthChief Scientific OfficeCamille L. BedrosianChief Medical Officer & Executive Vice PresidentThomas Richard KassbergChief Business Officer & Executive Vice PresidentKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMHUTCHMEDNASDAQ:HCMAbCellera BiologicsNASDAQ:ABCLACADIA PharmaceuticalsNASDAQ:ACADMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsTD Asset Management IncSold 132,214 shares on 2/7/2023Ownership: 0.186%WCM Investment Management LLCBought 6,715 shares on 2/7/2023Ownership: 0.138%Mitsubishi UFJ Kokusai Asset Management Co. Ltd.Bought 2,061 shares on 2/7/2023Ownership: 0.010%Oppenheimer Asset Management Inc.Bought 5,133 shares on 2/7/2023Ownership: 0.007%Emerald Advisers LLCSold 2,356 shares on 2/3/2023Ownership: 0.492%View All Insider TransactionsView All Institutional Transactions RARE Stock - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price forecast for 2023? 12 brokerages have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $50.00 to $142.00. On average, they predict the company's stock price to reach $91.69 in the next twelve months. This suggests a possible upside of 99.6% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2023? Ultragenyx Pharmaceutical's stock was trading at $46.33 at the start of the year. Since then, RARE stock has decreased by 0.8% and is now trading at $45.94. View the best growth stocks for 2023 here. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.35. The biopharmaceutical company had revenue of $81.65 million for the quarter, compared to analyst estimates of $78.16 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 84.14% and a negative net margin of 197.47%. During the same quarter in the previous year, the firm posted ($1.13) EPS. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). What is Ultragenyx Pharmaceutical's stock symbol? Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE." Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.49%), Emerald Mutual Fund Advisers Trust (0.36%), Assenagon Asset Management S.A. (0.23%), Peregrine Capital Management LLC (0.21%), Pinnacle Associates Ltd. (0.18%) and Pinnacle Associates Ltd. (0.18%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ultragenyx Pharmaceutical's stock price today? One share of RARE stock can currently be purchased for approximately $45.94. How much money does Ultragenyx Pharmaceutical make? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.22 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($9.74) on an earnings per share basis. How many employees does Ultragenyx Pharmaceutical have? The company employs 1,119 workers across the globe. How can I contact Ultragenyx Pharmaceutical? Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810. This page (NASDAQ:RARE) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.